Stock MANNKIND CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News MannKind Corporation Nasdaq

Equities

US56400P2011

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for MannKind Corporation
06-22 MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 Study CI
05-29 MannKind Agrees to Cross License Deal With Pulmatrix MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
AQ
MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 Study
CI
MannKind Corporation - Inhale-3 Study Results to be presented during a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions
AQ
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
AQ
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
AQ
MannKind Agrees to Cross License Deal With Pulmatrix
MT
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
AQ
Pulmatrix, Inc. Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
CI
MannKind : First Quarter 2024 Earnings Call Presentation
PU
MannKind: Q1 Earnings Snapshot
AQ
Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05
MT
Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, vs. Street Est of $60.6M
MT
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
AQ
MannKind Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
MannKind Receives FDA Fast Track Designation for its Potential Lung Disease Treatment
MT
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
AQ
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease
CI
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
AQ
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MNKD Stock
  4. Stock
  5. News MannKind Corporation